Differences in Virological and Immunological Risk Factors for Non-Hodgkin and Hodgkin Lymphoma

Author:

Shepherd Leah1,Ryom Lene2,Law Matthew3,Hatleberg Camilla Ingrid2,de Wit Stephane4,Monforte Antonella d'Arminio5,Battegay Manuel6,Phillips Andrew1,Bonnet Fabrice7,Reiss Peter8,Pradier Christian9,Grulich Andrew3,Sabin Caroline1,Lundgren Jens2,Mocroft Amanda1

Affiliation:

1. Research Department of Infection and Population Health, UCL, London, UK

2. CHIP, Department of Infectious Diseases, Section 2100, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

3. The Kirby Institute, UNSW Australia, Sydney, Australia

4. Division of Infectious Diseases, Saint Pierre University Hospital, Université Libre de Bruxelles, Brussels, Belgium

5. Dipartimento di Scienze della Salute, Clinica di Malattie Infectitive e Tropicali, Azienda Ospedaliera-Polo Universitario San Paolo, Milan, Italy

6. Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, University of Basel, Basel, Switzerland

7. CHU de Bordeaux and INSERM U1219, Université de Bordeaux, Bordeaux, France

8. Academic Medical Center, Division of Infectious Diseases, Department of Global Health, University of Amsterdam, and HIV Monitoring Foundation, Amsterdam, the Netherlands

9. Department of Public Health, Nice University Hospital, Nice, France

Abstract

AbstractBackgroundNon-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) are increased in populations with immune dysfunction, including people living with HIV; however, there is little evidence for to what degree immunological and virological factors differently affect NHL and HL risk.MethodsData from the Data Collection on Adverse events of Anti-HIV Drugs Study cohort were analyzed to identify independent risk factors for NHL and HL using hazard ratios (HRs), focusing on current and cumulative area under the curve (AUC) measures of immunological and virological status. Variables with different associations with NHL and HL were identified using marginal Cox models. All statistical tests were two-sided.ResultsAmong 41 420 people followed for 337 020 person-years, 392 developed NHL (incidence rate = 1.17/1000 person-years of follow-up [PYFU], 95% confidence interval [CI] = 1.06 to 1.30) and 149 developed HL (incidence rate = 0.44/1000 PYFU, 95% CI = 0.38 to 0.52). Higher risk of both NHL and HL was associated with lower current CD4 cell count (adjusted HR [aHR] of NHL for CD4 <100 vs > 599 cells/mm3 = 8.08, 95% CI = 5.63 to 11.61; HL = 4.58, 95% CI = 2.22 to 9.45), whereas higher current HIV viral load (aHR of NHL for HIV-VL >1000 vs < 50 copies/mL = 1.97, 95% CI = 1.50 to 2.59) and higher AUC of HIV-VL (aHR of NHL for highest vs lowest quintile = 2.91, 95% CI = 1.92 to 4.41) were associated with NHL only. Both current and AUC of HIV-VL were factors that had different associations with NHL and HL, where the hazard ratio for NHL was progressively higher than for HL with increasing HIV-VL category. Lower current CD4 cell count had a strong but similar association with both NHL and HL.ConclusionsCD4 depletion increased risk of both types of lymphomas while current and accumulated HIV-VL was associated with NHL only. This suggests that NHL development is related to both CD4 cell depletion and added immune dysfunction derived from ongoing HIV replication. This latter factor was not associated with HL risk.

Funder

Highly Active Antiretroviral Therapy Oversight Committee

European Agency for the Evaluation of Medicinal Products

United States Food and Drug Administration

AbbVie

Bristol-Myers Squibb

Gilead Sciences Inc.

ViiV Healthcare

Merck & Co Inc.

Janssen Pharmaceuticals

Danish National Research Foundation

Dutch Ministry of Health, Welfare and Sport

Center for Infectious Disease Control of the National Institute for Public Health and the Environment

Agence Nationale de Recherches sur le SIDA et les Hépatites Virales

The Australian HIV Observational Database

Asia Pacific HIV Observational Database

Foundation for AIDS Research

S National Institutes of Health

National Institute of Allergy and Infectious Diseases

Merck Sharp & Dohme

Gilead Sciences

Boehringer Ingelheim

Janssen-Cilag

Kirby Institute

Australian Government Department of Health and Ageing

Faculty of Medicine, University of New South Wales

Fondo de Investigación Sanitaria

Fundación para la Investigación y la Prevención del SIDA en Espanã

Barcelona Antiretroviral Surveillance Study

Terry Beirn Community Programs for Clinical Research on AIDS

European Union’s Seventh Framework Programme for research, technological development, and demonstration

Janssen R&D, Merck and Co. Inc.

Pfizer Inc.

GlaxoSmithKline LLC

Swiss National Science Foundation

Italian Cohort Naive to Antiretrovirals

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3